Immune peptide research usually clusters around three levels: direct anti-inflammatory signaling, adaptive immune support, and neuroimmune cross-talk. KPV, Thymosin Alpha 1, and VIP fit those lanes respectively, even though real protocols often overlap more than the categories suggest.

That three-level view is helpful because it keeps the category honest. Not every immune peptide is interchangeable. Some questions are really about cytokine tone or NF-kB. Some are about T-cell maturation and immune competence. Some are about how neural and immune signaling intersect under stress.

1. Thymosin Alpha 1 — strongest overall evidence because immune research extends into clinical and regulatory history.
2. KPV — strongest in anti-inflammatory and barrier-linked preclinical conversations.
3. VIP — strongest when the protocol is explicitly about neuroimmune signaling and peptide-mediated communication.
4. KLOW — useful when the immune question overlaps heavily with repair and remodeling.

Single-compound immune protocols make the most sense when the question is mechanistic. Stacks become more attractive when the immune question sits inside a larger recovery or remodeling problem. That is why KLOW can matter in immune-adjacent work even though its most distinctive feature is being a multi-pathway stack rather than a single immune molecule.

The right immune peptide is therefore the one that matches the level of the question: inflammatory signaling, adaptive immunity, or integrated immune-plus-repair biology.